Comparison of Efficacy and Complication of Alteplase Injection in Acute Ischemic Stroke
Archives of Medical Laboratory Sciences,
Vol. 7 (2021),
13 March 2021
,
Page 1-6 (e4)
https://doi.org/10.22037/amls.v7.33501
Abstract
Background and Aim: Alteplase is a thrombolytic drug that is produced by recombinant DNA technology. Tissue plasminogen activator enzyme which converts plasminogen to the active form of plasmin is also produced by the same technology; it causes fibrinolysis and clot dissolution. This study aimed to compare the efficacy and complications of Alteplase injection in patients with acute ischemic stroke (AIS( during the first 3 hours and 3-4.5 hours after the onset of symptoms.
Methods: In this study, patients with AIS who were referred to Golestan Hospital of Ahvaz city during 2018-2019 were selected. Information was collected by a checklist.
Results: The results showed that the mean Modified Rankin Scale (mRS) for 3 months and 6 months (p-value: 0.91 for 3 months and p-value: 0.80 for 6 months) and National Institutes of Health Stroke Scale (NIHSS) (p-value: 0.21) were not significantly different between both groups; statistically, no significant relationship was observed between them. The incidence of complications after treatment was almost similar, in both groups.
Conclusion: Finally, it was concluded that complications and efficacy of rt-PA (Alteplase) injection were not statistically different, between the two groups under study.
*Corresponding Author: Gholamreza Shamsaei; Email: grshamsaei@gmail.com; shamsaei-gh@ajums.ac.ir
Please cite this article as: Amirazodi E, Shamsaei G, Rafie S, Kashipazha D, Hesam S. Comparison of Efficacy and Complication of Alteplase Injection in Acute Ischemic Stroke. Arch Med Lab Sci. 2021;7:1-6 (e4). https://doi.org/10.22037/amls.v7.33501
- Alteplase
- Acute Ischemic Stroke (AIS)
- Side Effects
- Treatment
- Timing
How to Cite
References
Yayan J. Effectiveness of Alteplase in the very elderly after acute ischemic stroke. Clinical Interventions in Aging. 2013;8:963-74.
Jiang MQ, Zhao YY, Cao W, Wei ZZ, Gu X, Wei L, et al. Long‐term survival and regeneration of neuronal and vasculature cells inside the core region after ischemic stroke in adult mice. Brain Pathology. 2017;27(4):480-98.
Bansal S, Sangha KS, Khatri P. Drug treatment of acute ischemic stroke. American Journal of Cardiovascular Drugs. 2013;13(1):57-69.
del Zoppo GJ, editor Plasminogen activators and ischemic stroke: conditions for acute delivery. Semin Thromb Hemost. 2013 Jun;39(4):406-25.
Micieli G, Marcheselli S, Tosi PA. Safety and efficacy of Alteplase in the treatment of acute ischemic stroke. Vascular Health and Risk Management. 2009;5:397.
Sun Y-Y, Morozov YM, Yang D, Li Y, Dunn RS, Rakic P, et al. Synergy of combined tPA-edaravone therapy in experimental thrombotic stroke. PLoS One. 2014 Jun 9;9(6):e98807.
Xu Z-P, Li H-H, Li Y-H, Zhang Y, Wu Q, Lin LJJoCN. Feasibility and outcomes of intravenous thrombolysis 3–4.5 hours after stroke in Chinese patients. 2014;21(5):822-6.
Li YH, Li MH, Zhao JG, Wang WJJoN. MRI‐Based Ultrafast Protocol Thrombolysis with rt‐PA for Acute Ischemia Stroke in 12‐Hour Time Window. 2011;21(4):332-9.
MARLER JJAoahwnng, org. hws-s. Proceedings of a National Symposium on Rapid Identification and Treatment of Acute Stroke. The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health. 1997. Available online at http://www. ninds. nih. gov and http://www. stroke-site. org. 1997.
Tekle WG, Chaudhry SA, Fatima Z, Ahmed M, Khalil S, Hassan AE, et al. Intravenous thrombolysis in expanded time window (3-4.5 hours) in general practice with concurrent availability of endovascular treatment. 2012 Jun;5(1):22-6.
Shobha N, Buchan AM, Hill MD, diseases CAfSESIJC. Thrombolysis at 3–4.5 hours after acute ischemic stroke onset–evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. 2011;31(3):223-8.
Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. 2008;359(13):1317-29.
Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study: a randomized controlled trial. 1999;282(21):2019-26.
- Abstract Viewed: 248 times
- PDF Downloaded: 120 times